More than 6,000 middle-aged and older Hispanic and Latino adults enrolled in a major federal health study are showing blood-based signatures of Alzheimer’s disease pathology, and the strongest predictor of those signatures is diabetes. The SOL-INCA ancillary study, built on the Hispanic Community Health Study/Study of Latinos infrastructure, found that diabetes status and higher HbA1c levels tracked with elevated p-tau181 and a lower ratio of amyloid-beta 42 to 40 in plasma, a pattern that mirrors the amyloid-tau-neurodegeneration framework used to classify Alzheimer’s disease biologically. The findings raise an urgent question for a population that already faces disproportionate rates of both diabetes and dementia: can better blood sugar control slow or prevent these brain-related changes before symptoms appear?
Why blood biomarkers in Latino adults demand attention now
The connection between diabetes and cognitive decline is not new, but the SOL-INCA results sharpen the picture in a specific way. Rather than relying on expensive PET scans or spinal taps, researchers measured Alzheimer’s-associated proteins directly in blood samples drawn from a large, community-based cohort. The study, published in a leading Alzheimer’s journal, reported that participants with diabetes or poorly controlled blood sugar showed higher concentrations of p-tau181, a marker of tau phosphorylation tied to early Alzheimer’s pathology, alongside lower ratios of amyloid-beta 42 to 40, which signal abnormal amyloid processing in the brain.
These are not abstract laboratory curiosities. Separate research using the same cohort found that the identical plasma biomarkers, including p-tau181, the amyloid-beta 42/40 ratio, neurofilament light chain, and glial fibrillary acidic protein, are directly associated with cognitive performance among Hispanic and Latino adults. In plain terms, the blood signals linked to diabetes in this population also predict how well people think, remember, and process information. That dual association turns a metabolic risk factor into a potential early warning system for neurodegeneration.
One hypothesis worth tracking is whether sustained reductions in HbA1c, on the order of one percentage point or more between the study’s two main clinical visits, correspond to slower increases in p-tau181 and more stable amyloid-beta ratios at the SOL-INCA blood draw. No individual-level longitudinal biomarker trajectory data from the study has been released publicly to test this idea, but the HCHS/SOL data architecture, which includes Visit 1, Visit 2, and the INCA ancillary study in its BioLINCC archive, makes such an analysis structurally possible. If better glucose control does blunt these Alzheimer’s-style blood signals, it would offer a concrete, actionable target for prevention in a high-risk group.
How SOL-INCA built the evidence base for this finding
The strength of these results rests heavily on the study’s design. SOL-INCA was not a convenience sample or a small clinic-based project. It was constructed as an ancillary investigation layered onto the HCHS/SOL framework, a multi-site, population-based cohort study funded by the National Heart, Lung, and Blood Institute that enrolled participants from communities in the Bronx, Chicago, Miami, and San Diego. That infrastructure gave SOL-INCA standardized sampling, repeat clinical visits, and neurocognitive testing protocols that few studies of Latino brain health can match.
The parent cohort’s structure is described in detail in a methodological report that outlines how participants were recruited, examined, and followed over time. Because SOL-INCA drew from that well-characterized base, investigators could link plasma biomarkers to a rich set of clinical measures, including fasting glucose, HbA1c, blood pressure, lipid profiles, and cognitive test batteries. That linkage allowed them to adjust for potential confounders such as age, sex, education, and vascular risk factors when estimating the relationship between diabetes and Alzheimer’s-related proteins.
The biomarker panel itself reflects the current scientific consensus on blood-based Alzheimer’s detection. Plasma p-tau181 has been validated across multiple ethnic groups as a marker of early tau pathology, and the amyloid-beta 42/40 ratio serves as a peripheral proxy for brain amyloid burden. Multi-ethnic community studies such as WHICAP have confirmed that these markers behave consistently across diverse populations, though baseline distributions can differ by ethnicity. Research comparing biomarker levels in Hispanic versus non-Hispanic White adults has shown that associations with dementia risk can vary between groups, which is precisely why population-specific evaluation through studies like SOL-INCA matters. Without dedicated data from Latino cohorts, clinicians risk applying thresholds and risk models calibrated to populations that may not share the same biological starting points.
Open questions about glucose control and Alzheimer’s blood signals
Several gaps in the evidence limit how far these findings can be pushed. The SOL-INCA analysis established a cross-sectional association between diabetes, HbA1c, and Alzheimer’s biomarkers, but it did not demonstrate that high blood sugar causes the biomarker changes. Reverse causation or shared upstream factors, such as chronic inflammation or vascular damage, could explain part of the relationship. No effect-size tables or adjusted risk estimates from randomized interventions are available to show that improving glucose control will necessarily normalize p-tau181 or amyloid-beta ratios.
Timing is another unresolved issue. The participants in SOL-INCA were generally middle-aged or older, with many already living with diabetes for years. It is unclear whether the observed biomarker patterns emerge only after prolonged exposure to hyperglycemia or whether they begin to shift earlier in the disease course. If the latter is true, there may be a critical window in midlife when aggressive diabetes prevention or treatment could have the greatest impact on Alzheimer’s-related pathology. Answering that question will require repeated blood biomarker measurements over time, something the current SOL-INCA dataset does not yet provide.
There are also questions about heterogeneity within the Hispanic and Latino population itself. HCHS/SOL includes individuals with backgrounds in Mexico, Puerto Rico, Cuba, Central and South America, and the Dominican Republic, among others. Cultural, genetic, and environmental differences across these groups could influence both diabetes risk and Alzheimer’s biomarker trajectories. While the overall association between HbA1c and p-tau181 appears robust, future analyses may reveal that the strength or clinical implications of that link vary by heritage group, socioeconomic status, or access to health care.
Finally, the clinical meaning of a single elevated p-tau181 value in an otherwise cognitively normal adult remains uncertain. Even if diabetes is associated with higher average levels of this marker, not every individual with diabetes will develop dementia, and some people without diabetes will. Translating group-level biomarker trends into personalized risk predictions will require integrating blood measures with genetic data, imaging findings, and longitudinal cognitive outcomes.
Implications for prevention, care, and policy
Despite these uncertainties, the SOL-INCA findings carry practical implications. For clinicians caring for Hispanic and Latino adults, they reinforce the importance of aggressive diabetes prevention and management, not only to protect the heart and kidneys but also potentially to safeguard the brain. Discussing cognitive health when setting HbA1c goals may resonate with patients who have seen family members struggle with dementia.
For researchers, the study underscores the value of investing in diverse, community-based cohorts with long-term follow-up and biospecimen collection. The same infrastructure that enabled SOL-INCA to link diabetes with Alzheimer’s biomarkers could support future trials that test whether lifestyle interventions, medications, or health system changes can modify those markers over time. Embedding randomized interventions within existing cohorts may be a cost-effective way to move from association to causation.
At the policy level, the convergence of high diabetes prevalence, elevated dementia risk, and emerging Alzheimer’s blood biomarkers in Hispanic and Latino communities argues for targeted public health strategies. Expanding access to diabetes screening, culturally tailored nutrition and physical activity programs, and affordable primary care could yield benefits that extend beyond traditional cardiometabolic outcomes. As blood tests for Alzheimer’s disease move closer to clinical practice, ensuring that they are validated and interpreted appropriately in Latino populations will be essential to avoid widening existing health disparities.
Taken together, the SOL-INCA data do not yet prove that controlling blood sugar will prevent Alzheimer’s disease. They do, however, illuminate a biological pathway through which diabetes may shape brain aging in a population that has often been underrepresented in dementia research. By following that pathway with careful longitudinal studies and inclusive clinical trials, scientists and clinicians may find new opportunities to delay or reduce the burden of cognitive decline for millions of Hispanic and Latino adults.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
